SCP
RVMD icon

Sender Company & Partners’s Revolution Medicines RVMD Stock Holding History

Sender Company & Partners’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8,637
Closed -$403K – 379
2025
Q3 		$403K Buy
+8,637
New +$338K 0.04% 288

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sender Company & Partners's RVMD Position: Q4 2025 in Review

Sender Company & Partners sold out of Revolution Medicines (RVMD) in Q4 2025, closing a stake of 8,637 shares — an estimated $403K sold.

Sender Company & Partners first reported a position in RVMD in Q3 2025 and held it in 1 quarter. The position peaked at $403K in Q3 2025. 386 funds tracked by Wall St. Rank hold RVMD as of Q4 2025.

  • Sender Company & Partners reported no remaining Revolution Medicines position as of Q4 2025 after selling out during the quarter.
  • Sender Company & Partners sold 8,637 Revolution Medicines shares in Q4 2025, an estimated $403K.
  • Sender Company & Partners first reported a position in Revolution Medicines in Q3 2025 and held it in 1 quarter.
  • Sender Company & Partners's Revolution Medicines position peaked at $403K in Q3 2025.
  • 386 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2025.

Based on Sender Company & Partners's 13F filing for Q4 2025, filed 17 Feb 2026.